Related Experiment Video
Updated: Dec 25, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide
Huijie Jia1, Jing Guo2, Pingping Wang3
1Institute of Precision Medicine, Xinxiang Medical University, 601 Jinsui Road, Xinxiang 453007, China; Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, Xinxiang Medical University, Xinxiang, China; Department of Pathology, Xinxiang Medical University, Xinxiang, China.
Abstract:
Melanomas represent the deadliest form of skin cancers. Due to the intricacy of tumorigenesis, it is emergent to find effective therapies for melanomas. Researches have proved that pimozide inhibits the growth of melanoma, but the limited curing effect needs to be further improved. Nowadays, tumor immunotherapy has been widely recognized as the sole therapy that can eradicate cancers. Cytosine-phosphate-guanine oligodeoxynucleotide (CpG ODN), TLR9 receptor agonist, can significantly enhance anti-tumor immune responses. This study explored the therapeutic effect of pimozide combined with CpG ODN on melanoma-bearing mice. The results showed that pimozide combined with CpG ODN effectively inhibited the growth of melanoma and prolonged the survival of melanoma-bearing mice, inhibited the expression of MMP2 and p-Stat5, increased the infiltration of CD4+ and CD8+ T cells in tumor, raised the ratios of CD4+, CD8+ T cells and NK cells. These all indicated that the combination treatment improved the anti-tumor effect of pimozide on mice. The anti-tumor mechanism might be attributed to cell apoptosis induction, invasion inhibition, and immune regulation. A more effective combination treatment concerning with pimozide is being under investigation.
Insights
This study shows that combining pimozide with CpG oligodeoxynucleotides (CpG ODN) effectively inhibits melanoma growth and enhances anti-tumor immunity in mice. This combination therapy offers a promising strategy for improving melanoma treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Melanoma is an aggressive skin cancer requiring novel therapeutic strategies.
- Pimozide demonstrates melanoma growth inhibition, but its efficacy needs enhancement.
- Tumor immunotherapy, particularly using Toll-like receptor 9 (TLR9) agonists like CpG ODN, shows promise in cancer eradication.
Purpose of the Study:
- To investigate the combined therapeutic effects of pimozide and CpG ODN in a melanoma mouse model.
- To evaluate the impact of this combination therapy on tumor growth, survival, and immune cell profiles.
Main Methods:
- Melanoma-bearing mice were treated with pimozide alone, CpG ODN alone, or a combination of both.
- Tumor growth, survival rates, and immune cell infiltration (CD4+, CD8+ T cells, NK cells) were assessed.
- Expression levels of MMP2 and p-Stat5 were analyzed.
Main Results:
- The combination of pimozide and CpG ODN significantly inhibited melanoma tumor growth and prolonged mouse survival.
- Combined treatment suppressed MMP2 and p-Stat5 expression.
- Increased infiltration and ratios of CD4+, CD8+ T cells, and NK cells were observed in tumors.
Conclusions:
- Pimozide combined with CpG ODN demonstrates enhanced anti-melanoma efficacy compared to monotherapy.
- The combination therapy may exert its effects through inducing apoptosis, inhibiting invasion, and modulating the immune response.
- Further research into optimized combination therapies involving pimozide is warranted.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...

